High CCR5 expression in natalizumab-associated progressive multifocal leukoencephalopathy immune reconstitution inflammatory syndrome supports treatment with the CCR5 inhibitor maraviroc

Acta Neuropathol. 2015 Mar;129(3):467-8. doi: 10.1007/s00401-015-1391-6. Epub 2015 Jan 22.

Authors

Lidia Stork¹, Wolfgang Brück, Amit Bar-Or, Imke Metz

Affiliation

¹ Department of Neuropathology, University Medical Center Göttingen, Robert-Koch-Str. 40, 37075, Göttingen, Germany.

PMID: 25604548
DOI: 10.1007/s00401-015-1391-6

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

B-Lymphocytes / metabolism
CCR5 Receptor Antagonists / therapeutic use*
CD4-Positive T-Lymphocytes
CD8-Positive T-Lymphocytes / metabolism
Cyclohexanes
Humans
Immune Reconstitution Inflammatory Syndrome / drug therapy*
Immune Reconstitution Inflammatory Syndrome / etiology
Immune Reconstitution Inflammatory Syndrome / metabolism
Leukoencephalopathy, Progressive Multifocal / drug therapy*
Leukoencephalopathy, Progressive Multifocal / etiology
Leukoencephalopathy, Progressive Multifocal / metabolism
Maraviroc
Multiple Sclerosis / drug therapy
Natalizumab / therapeutic use
Receptors, CCR5 / biosynthesis*
Triazoles

Substances

CCR5 Receptor Antagonists
Cyclohexanes
Natalizumab
Receptors, CCR5
Triazoles
Maraviroc